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Lichen planus (LP) is an uncommon mucocutaneous inflammatory condition, that is
immunologically mediated, typically pruritic and often recurs. The currently advocated
therapies are either not highly effective or associated with severe side effects.
Enoxaparin, a widely used anticoagulant, is composed of both anticoagulant and non-
anticoagulant fragments. Enoxaparin is reported to have anti-inflammatory properties
and it was found to be effective in LP. However, the results from clinical studies have
varied substantially and, therefore, the clinical role of enoxaparin in LP remains uncertain.
This review focuses on potential reasons for the reported inconsistent outcomes, as well
as proposing solutions; these include identifying batch-to-batch inconsistency in the
composition of enoxaparin. The potential therapeutic value of enoxaparin in LP must
be explored using well-designed clinical trials, combined with experimental studies that
focus on identifying the anti-inflammatory fragments of enoxaparin and elucidating the
mechanism of action of these non-anticoagulant fragments.
Keywords: anti-inflammatory, batch-to-batch variation, chromatography, enoxaparin, heparin, lichen planus,
non-anticoagulant, response
INTRODUCTION
Lichen planus (LP) is a mucocutaneous inflammatory condition that can present with a variety
of clinical manifestations. It mainly affects the skin, nails, scalp, and oral and genital mucous
membranes. It is characterized by itchy, purplish, polygonal, flat-topped papules with lacy white
lines (Wickham’s striae) (Gorouhi et al., 2014; Weston and Payette, 2015). The precise prevalence
of LP is unknown but is estimated to be between 0.22 and 5% worldwide (Gorouhi et al., 2014).
It can be associated with hepatitis C viral infection (Shengyuan et al., 2009). Without therapy, the
skin lesions usually resolve over 6–18 months, although in up to 20% of patients relapse occurs
in the same area as the initial episode (Gorouhi et al., 2014). Chronic disease is more likely with
oral LP.
The etiology of LP is yet to be fully understood, but an immunological abnormality is believed to
play an important role, notably involving antigen-presenting cells. Evidence so far suggests that LP
is associated with T-cell mediated inflammation, in particular increased expression of heparanase
and activation of keratinocytes (Daoud and Pittelkow, 2012). Patients with LP are reported to
have elevated levels of several inflammatory mediators (tumor necrosis factor alpha (TNF-α),
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interleukin (IL)-2, IL-4, IL-6, IL-10 and basic fibroblast growth
factor), correlating with the severity of the condition (Simark-
Mattsson et al., 1999; Pezelj-Ribaric et al., 2004; Gorugantula
et al., 2012; Kaur and Jacobs, 2015). These inflammatory
mediators stimulate the accumulation of T cells in the epidermis,
ultimately resulting in destruction of the epidermis, referred to as
a lichenoid tissue reaction.
A wide range of therapeutic approaches, including topical,
systemic and intralesional corticosteroids, antihistamines,
calcineurin inhibitors (e.g., cyclosporine, pimecrolimus,
sirolimus, and tacrolimus), sulfasalazine, systemic and topical
retinoids, aloe vera, and extracorporeal photo-chemotherapy,
has been used for the treatment of the various forms of LP
(Farhi and Dupin, 2010). However, the lack of evidence for
efficacy of the currently advocated pharmacological agents, as
well as their potential for significant side effects, can make the
treatment frustrating for both clinicians and patients (Farhi
and Dupin, 2010). Therefore, the search for safer and more
effective modalities for the management of LP continues.
Enoxaparin, a type of glycosaminoglycan, has attracted much
interest among researchers due to its reported anti-inflammatory
properties.
ENOXAPARIN
Enoxaparin, the first low-molecular-weight heparin (LMWH)
approved by the Food and Drug Administration, has an average
molecular weight of 4500 Da. Enoxaparin has largely replaced
unfractionated heparin in clinical practice due to its fewer side
effects, higher anti-factor (AFXa) activity and more predictable
dose-response relationship (Dekker et al., 2016). As shown in
Figure 1A, it is a highly negatively charged linear polysaccharide
composed of repeating disaccharide units of D-glucosamine and
uronic acid linked by 1→4 glycosidic bonds (Perkins et al.,
2014). Enoxaparin is obtained by controlled chemical eliminative
cleavage of the benzyl ester of heparin with alkaline treatment.
This process results in the formation of LMW chains, of
which typically 15–25% contain a 1,6-anhydroglucosamine at the
reducing end (Figure 1B) (Perkins et al., 2014).
Non-anticoagulant Fragments of
Enoxaparin and Inflammation
Enoxaparin is known to have a wide range of biological activities.
It is a mixture of highly negatively charged, structurally complex
fragments (dp2 – two saccharides to approximately dp22 –
twenty two saccharides) with undefined structure and inherent
variability. Enoxaparin possesses both anticoagulant and non-
anticoagulant fragments, with substantial evidence that the latter
fragments are accountable for the reported anti-inflammatory
effects of enoxaparin. For example, in an in vitro study, lung
epithelial cells were stimulated to release two inflammatory
cytokines, IL-6 and IL-8. Stimulated cells were treated with either
enoxaparin or its various fragments. The disaccharide fragments
(dp2) without anticoagulant activity were found to be responsible
for the anti-inflammatory effect of enoxaparin (Shastri et al.,
2015b). In another study, peripheral blood mononuclear cells
from patients with allergic inflammation were activated in the
presence or absence of enoxaparin fragments before measuring
the levels of inflammatory cytokines (Shastri et al., 2015c). Two
fragments of enoxaparin without anticoagulant activity were
found to be responsible for the inhibition of cytokine secretion.
A disaccharide fragment (dp2) inhibited the release of IL-4, IL-5,
IL-12, and TNF-α by more than 57%, while a tetrasaccharide
fragment (dp4) inhibited the release of these cytokines by 68%.
Lean et al. (2014) identified various fragments of enoxaparin
with pro- and anti-proliferative effects. The authors treated
the human colonic epithelial cancer cells in the presence of
enoxaparin or its various fragments. Interestingly, the smallest
fragment of enoxaparin (dp2), devoid of any anticoagulant
activity, showed the strongest anti-proliferative effect (Lean
et al., 2014). Shastri et al. (2013) investigated the ability of
enoxaparin-derived fragments to inhibit nitric oxide production
by lipopolysaccharide-activated macrophages. The disaccharide
fragment of enoxaparin did not exhibit any anticoagulant activity
but it reduced the production of nitric oxide by 50%. In a
FIGURE 1 | The disaccharide contains two residues of uronic acid and d-glucosamine linked by a 1→4 glycosidic linkage (A). Approximately 15–25% of enoxaparin
oligosaccharides contain 1,6-anhydro groups at their reducing end (B) as a result of chemical b-eliminative cleavage of unfractionated heparin. Reproduced with
permission (Patel et al., 2009c).
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preclinical study, male C57BL/6 mice with chemically induced
intestinal inflammation were treated with various fragments of
enoxaparin. The tetrasaccharide fragments (dp4) of enoxaparin
prevented the increase of relative colon weight, and the
hexasaccharides (dp6) selectively reduced shortening of the colon
(Lean et al., 2016). The authors reported that the identified
active tetrasaccharides did not exert anticoagulant activity and
the hexasaccharides had a low risk of bleeding, as the measured
anticoagulant activity was reduced 10-fold compared to parent
enoxaparin.
Clinical Use of Enoxaparin in LP
Topical and intralesional corticosteroids are the current first-
line therapy for LP (Lebwohl et al., 2017). However, large scale
randomized clinical trials are still warranted to establish the
efficacy of corticosteroids, as well as other available modalities
for different variants of LP (Atzmony et al., 2016). At present,
drug treatments for LP are either not completely effective and/or
associated with severe side effects (Atzmony et al., 2016). LP can
be chronic and relapsing in nature, and is often resistant to the
currently available pharmacological agents. Therefore, the search
for more effective and safer therapeutic agents for the treatment
of LP continues.
Enoxaparin is the only derivative of heparin that has been
so far evaluated for its clinical efficacy in LP. The studies have
reported mixed but encouraging clinical outcomes. Ingber et al.
(1994) demonstrated that low subcutaneous doses of enoxaparin
inhibited the elicitation of allergic contact dermatitis. This
preliminary finding led to the investigation of enoxaparin in
11 patients with histopathologically proven LP (Hodak et al.,
1998). Subcutaneous injection of 3 mg of enoxaparin once-weekly
for either 4 or 6 weeks resulted in complete regression of the
eruption, with residual post-inflammatory hyperpigmentation in
more than 70% of patients (8 out of 11). On the basis of these
encouraging early findings, the potential role of enoxaparin in LP
was further explored by researchers internationally.
To date, one randomized clinical trial, and twelve small, open-
labeled and non-randomized clinical studies have investigated the
therapeutic efficacy of subcutaneously administered enoxaparin
in LP (Table 1). Stefanidou et al. (1999) evaluated the efficacy
of enoxaparin in 18 patients with various types of LP and
reported complete remission in 61% of patients and marked
improvement in a further 11%. Similarly, Pacheco and Kerdel
(2001) reported marked improvement in 5 out of 7 patients with
LP when treated with enoxaparin. In another study, patients
with LP were treated with enoxaparin for 4–14 weeks and 21
of 24 patients achieved complete remission (Akdeniz et al.,
2005). Similarly, once-weekly use of enoxaparin over a period of
20 weeks resulted in a dramatic improvement in visual analog
scale assessments of pain and itch in 13 out of 15 patients
unresponsive to topical or oral corticosteroid therapy (Ameen
and Alfadhily, 2011). Yasar et al. (2011) reported complete
remission of palmoplantar hyperkeratotic LP (HPLP), a relatively
uncommon form of LP that is mostly resistant to conventional
treatments, in 2 patients treated with enoxaparin for 3 months
(Yasar et al., 2011). No recurrence of PHLP was noted in follow-
ups performed over a period of 1 year. Khan et al. (2014) treated
cutaneous LP with enoxaparin for 6 weeks. They reported disease
improvement in 26 out of 31 patients. Ucmak and co-workers
reported distinctive recovery of the disease in 71% of patients
(15 out of 21) treated with enoxaparin for 12 weeks (Uçmak
et al., 2012). Neville et al. (2007) demonstrated a sustained clinical
response to enoxaparin in a patient with recalcitrant ulcerative
LP resistant to oral corticosteroids. All of the reports above used
3 mg of subcutaneous enoxaparin once-weekly and reported that
the therapy was well tolerated and was not associated with any
major side effects.
However, some clinical studies have shown disappointing
results. For example, 3 mg subcutaneous enoxaparin was
administered once-weekly for a period of 6 weeks to 10 patients
with proven LP (with or without oral lesions) (Rai et al., 2002).
None of the patients showed clinical remission at the end of the
study. Side effects, such as skin necrosis or multiple lesions with
increased itching, were observed in 20% of patients not allergic to
enoxaparin, heparin, or its derivatives. The observed side effects
were severe enough to require discontinuation of enoxaparin.
Ferahbas et al. (2003) presented a study in which 7 patients with
histologically proven LP were treated with 5 mg of subcutaneous
enoxaparin once-weekly for 6 weeks. Mild clinical improvement
was observed in only 1 patient and the other 6 patients did not
show improvement.
Another study compared the efficacy and safety of
methotrexate and enoxaparin in patients with generalized
LP, with a 6-month follow up (Lunge et al., 2016). Although
5 mg of subcutaneous enoxaparin administered once weekly for
16–24 weeks produced remission of skin lesions in 13 out of 20
patients, 35% of patients showed relapse after discontinuation
of enoxaparin. The authors concluded that methotrexate was
not only more effective in terms of causing complete remission
of the disease, but also better tolerated and associated with
a lower recurrence rate than enoxaparin. An open-labeled,
uncontrolled study treated 37 cases of cutaneous LP with 3 mg
of enoxaparin once-weekly for 6 weeks. Complete remission
was not observed in any of the patients and the reported side
effects were local irritation, bruises and headache (Khan et al.,
2014). So far, only one randomized clinical trial investigated the
efficacy of enoxaparin in patients with disseminated LP (Iraji
et al., 2013). In this study, 25 patients were treated with 5 mg
of subcutaneous enoxaparin once-weekly for 8 weeks, and 23
patients with 0.5 mg/kg daily oral prednisolone until complete
remission was observed or for a maximum of 8 weeks. The
reported therapeutic response rate was statistically lower for
enoxaparin (32% complete remission) than oral prednisolone
(69.6% complete remission). However, the number of patients
with reported side effects were non-statistically fewer in the
enoxaparin group than the prednisolone group.
PROPOSED REASONS FOR REPORTED
INCONSISTENT CLINICAL OUTCOMES
It is important to note that heparins, including LMWHs such
as enoxaparin, have shown inconsistent outcomes when used in
other clinical conditions where a non-anticoagulation effect is
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required. For example, so far 19 clinical studies have investigated
the efficacy of heparin or its low molecular weight derivatives
in ulcerative colitis (UC), a chronic inflammatory condition
(Lean et al., 2015). Some studies reported a significant clinical
improvement while others have shown little or no clinical benefit
of heparins in this condition. Brazier et al. reported complete
remission in 4 of 6 patients with UC when treated with heparin
(Brazier et al., 1996). Similarly, 12 out 16 patients with severe
refractory UC treated with either intravenous or subcutaneous
heparin showed significant clinical improvement (Evans et al.,
1997). On the other hand, several randomized studies have
reported no clinical benefit of heparin over placebo when used
for the management of mild-to-moderate UC (Lean et al., 2015).
One study showed that heparin has an inhibitory effect
on methacholine-induced bronchoconstrictive response and,
therefore, could potentially be used for the management of
asthma (Ceyhan and Celikel, 1995). However, in another study
such an effect of heparin was not observed (Pavord et al., 1996).
The possible reasons behind the observed discrepancies in the
reported clinical outcomes when enoxaparin was used for the
management of LP are briefly discussed below.
Variable Study Designs
The duration and the dosage regimen of the treatment, and
sub-type and severity of the disease could affect the response.
For example, clinical studies so far investigating the potential
of enoxaparin in LP included the use of: (i) different treatment
durations (ranging from 4 to 24 weeks); (ii) different dosage
regimens of enoxaparin (e.g., 3 mg once-weekly for 6 weeks or
5 mg once-weekly for 24 weeks, or 30 mg bi-weekly for the
first 2 weeks and then 3 mg bi-weekly for the next 4 weeks);
(iii) different disease extent and severity (mild, moderate, severe,
active or refractory LP); (iv) different forms and types of LP
(cutaneous, ulcerative, disseminated, generalized, recalcitrant,
localized, hypertrophic, palmoplantar etc.); and (v) inconsistent
study end points (remission of disease symptoms, self-reported
visual analog scales, histologic improvement etc.). Apart from
these explanations, the reported inconsistent clinical outcomes
could be due to the (i) use of sub-therapeutic dose of enoxaparin
and/or (ii) presence of compositional variation in different
batches of enoxaparin.
Use of Sub-Therapeutic Dose of
Enoxaparin
In clinical practice, enoxaparin is normally used for the
prevention and treatment of venous thromboembolic disorders,
including deep vein thrombosis and pulmonary embolism. The
prophylactic dose of enoxaparin in patients with a low-to-
moderate risk of venous thromboembolism is 20 mg once
daily by subcutaneous injection. For the treatment of venous
thromboembolism, the recommended dose of enoxaparin in a
60 kg patient is 90 mg once daily. All the studies, except one,
investigating the role of enoxaparin in LP used the dose of
either 3 or 5 mg once-weekly (Table 1). An earlier report of
the successful use of 3 mg subcutaneous enoxaparin in contact
dermatitis (Ingber et al., 1994), a T-cell driven inflammatory
condition, triggered the use of the sane dose in subsequent studies
in patients with LP, also a T-cell mediated autoimmune disease.
Plasma concentrations of enoxaparin after 20 and 40 mg
subcutaneous administration are reported to be 1.6 and
3.8 µg/mL, respectively (Sanofi-Aventis Australia Pty Ltd., 2014).
Enoxaparin, in various in vitro, in vivo and ex vivo studies,
displayed its anti-inflammatory activities at concentrations much
higher than its plasma concentrations required to achieve an
anticoagulant effect. For example, an in vivo study testing the
individual non-anticoagulant fragments of enoxaparin for their
anti-inflammatory effects used the dose that corresponded to the
amount of each fragment present in intact enoxaparin (Lean et al.,
2016). The authors reported that the doses for non-anticoagulant
fragments were found to be significantly lower than the doses
required for their anti-inflammatory effect. In another study, a
LMWH was found to be more effective than placebo for treating
patients with UC when administrated by extended colon-release
tablets (Chande et al., 2010). However, the same benefits were
not seen when a LMWH was administered subcutaneously in
lower doses (Chande et al., 2010). The immunological activity
in LP correlates with the disease severity and the low doses of
enoxaparin used in previous studies to treat various forms of LP
may not be sufficient to elicit an optimal clinical effect.
Batch-to-Batch Inconsistency
The reported variable clinical efficacy of enoxaparin when used
for the treatment of LP could be because of the batch-to-batch
inconsistency in the enoxaparin formulation. Batch-to-batch
inconsistency could result in compositional differences between
fragments potentially responsible for the anti-inflammatory
effects of enoxaparin. The commercially available enoxaparin
is standardized only according to the anticoagulant activity; it
is not standardized for the non-anticoagulant fragments, which
could result in batch-to-batch variations in the presence of these
fragments. Patel et al. (2008) developed a capillary electrophoresis
method for fingerprinting batches of commercially available
enoxaparin. Surprisingly, the method clearly revealed six
compositional differences in two different batches of enoxaparin
manufactured by the same manufacturer.
The initial study that examined the effects of enoxaparin
in LP reported complete regression of the eruption in eight
out of the ten patients (Hodak et al., 1998). However, similar
outcomes were not observed in some subsequent studies, and it
was previously hypothesized that the compositional differences
between batches of enoxaparin may be responsible for the
inconsistent observations (Ferahbas et al., 2003; Akdeniz et al.,
2005).
POSSIBLE SOLUTIONS TO AVOID
INCONSISTENT CLINICAL OUTCOMES
Determination of Clinical Efficacy of
Non-anticoagulant Fragments in LP
We believe that the ideal solution is to obtain non-anticoagulant
fragments of enoxaparin, and examine the efficacy of each
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fragment against LP. There are two principal approaches
of obtaining non-anticoagulant fragments of enoxaparin.
One approach is through enzymatic or chemical digestion
of enoxaparin. Digestion processes, otherwise known as
depolymerisation, are often carried out at elevated temperatures.
The sulfation pattern of enoxaparin’s fragments is important for
the various non-anticoagulant activities (Wang, 2011; Shastri
et al., 2015c). At elevated temperatures, some of the fragments
undergo desulfation resulting in structural changes and potential
loss of their biological activity (Patel et al., 2009c). Enoxaparin
undergoes aggregation at low temperatures resulting in the
loss of its biological activity (Patel et al., 2009b). Digestion
processes also involve freeze-drying and, therefore, the fragments
of enoxaparin obtained after digestion may be structurally
and therapeutically different from the fragments prior to the
digestion process.
Another approach to obtain various fragments of enoxaparin
is through chromatographic techniques. Enoxaparin is difficult
to separate into its various fragments due to its high polarity,
negative charge and structural complexity. However, various
chromatographic techniques, such as capillary electrophoresis
(Patel et al., 2008), reversed-phase high-performance liquid
chromatography (Patel et al., 2009a) and, more recently,
ion-exchange chromatography have been developed and
validated for the separation of enoxaparin into its fragments
(Shastri et al., 2013). The later chromatographic technique
successfully separated enoxaparin into more than 20 various
fragments without prior chemical or enzymatic digestion
of parent enoxaparin. Using the same technique, other
studies have identified groups of fragments in enoxaparin
with high, low and no anticoagulant activity (Lean et al.,
2015, 2016; Shastri et al., 2015c). In addition, Shastri
et al. (2013) demonstrated the anti-inflammatory effect
of enoxaparin fragments separated through ion-exchange
chromatography.
The therapeutic effect of each non-anticoagulant fragment
obtained through chromatographic techniques should first
be investigated using preclinical animal models of LP. The
preclinical testing of non-anticoagulant fragments using an
animal model to determine the fragments responsible for the
efficacy of enoxaparin in LP is not a prerequisite before
evaluating such fragments in humans. However, apart from
providing information such as therapeutic efficacy and safety
parameters essential to design a clinical study, a preclinical study
would provide the dose-response relationship for each non-
anticoagulant fragment. It is important to note that all the studies
so far looking at the efficacy of enoxaparin in LP have admittedly
employed doses that were sub-therapeutic for anticoagulant
activity to minimize the risk of bleeding. However, as previously
noted, the anti-inflammatory activities of heparin are expressed
at higher concentrations, where anticoagulant effects and
hence bleeding predominate if anticoagulant fragments are
administered. The information on dose-response relationship is
crucial as enoxaparin’s fragments have shown dose-dependent
anti-inflammatory effects in ex vivo and in vitro studies (Shastri
et al., 2013, 2015b). Enoxaparin is composed of multiple
fragments containing the same number of saccharides. For
example, enoxaparin contains approximately 6 fragments that
are composed of four saccharides (dp4) (Shastri et al., 2013).
The relative percentile amount of one of the six dp4 fragments
in 500 µg/mL of enoxaparin is approximately 5% (2.5 µg/ml).
This fragment, when used at 2.5 µg/mL, was not able to
inhibit different types of inflammatory cytokines released from
activated human immune cells. However, at 20 µg/mL, the same
fragment inhibited the release of IL-4, IL-5, IL-13, and TNF-α
by more than 69, 70, 75, and 70%, respectively (Shastri et al.,
2015c).
Dose-response activity obtained from an animal model
would provide much needed guidance on the likely appropriate
dose of active fragments required to elicit therapeutic effects
in patients with LP. Therefore, preclinical studies followed
by clinical investigations may lead to a new formulation of
enoxaparin fragments that exhibit anti-inflammatory properties,
without significant anticoagulant activity. The development of
such a formulation can therefore serve as a novel therapeutic
approach for the treatment of LP. However, development
and regulatory approval of such a formulation would require
extensive validation and formulation steps that are likely to take
a long time to eventuate.
Monitoring Batch-to-Batch Consistency
Until a novel formulation of non-anticoagulant fragments
of enoxaparin is developed and subsequently approved by
regulatory agencies and commercially available, studies of
different doses of enoxaparin and with large number of
patients will provide better insight into the effectiveness
of this drug. A key aspect in determining the clinical
efficacy of commercially available enoxaparin in LP is the
necessity to maintain consistency in the non-anticoagulant
fragments between different batches. The best possible way
seems to be to obtain the standard chromatographic profiles
of non-anticoagulant fragments of a particular batch of
enoxaparin with a proven clinical value in LP. Other batches
of enoxaparin could then be verified for the batch-to-batch
uniformity by comparing the separation patterns of their non-
anticoagulant fragments against the standard chromatographic
profile.
WAY FORWARD
Efficacy of Other LMWHs in LP
Surprisingly, no study so far has investigated the efficacy of
unfractionated heparin or LMWHs other than enoxaparin.
LMWHs such as dalteparin, tinzaparin, nadroparin,
fondaparinax, and reviparin are also approved anticoagulants.
Dalteparin and enoxaparin have shown improved clinical
outcomes when used for the management of UC (Torkvist et al.,
1999; Dotan et al., 2001). On the other hand, no significant
beneficial effect was observed with the use of tinzaparin or
reviparin in patients with UC (Bloom et al., 2004; de Bievre et al.,
2007).
Low-molecular-weight heparins are obtained by enzymatic
degradation of heparin or through chemical processes. Currently
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available LMWHs have different in vitro and ex vivo non-
anticoagulant activities, physico-chemical characteristics and
pharmacodynamics. These derivatives also differ in terms of
their sulfation pattern, an important parameter for their non-
anticoagulant activity, as well as their ability to interact with
cellular proteins, endothelial cells and inflammatory cytokines
(Prandoni, 2003).
Interestingly, in one study the observed effect of enoxaparin
on the release of inflammatory cytokines was opposite to
dalteparin (Shastri et al., 2015a,c). Enoxaparin inhibited cytokine
release by more than 48%, whereas dalteparin increased their
release by more than 25%. Smaller fragments were responsible for
the inhibitory effect of enoxaparin and the larger fractions were
associated with the stimulatory effect of dalteparin. Therefore,
future studies should not only investigate the efficacy of other
LMWHs in LP, but also compare the clinical effects of various
LMWHs.
Structural Elucidation of Active
Non-anticoagulant Fractions of
Enoxaparin
It is estimated that only 30% of fragments in heparins are
composed of the pentasaccharide sequence responsible for
their anticoagulant activity. This pentasaccharide sequence
selectively binds to anti-thrombin, resulting in enhanced effects
of anti-thrombin on factor Xa. The structure of pentasaccharide
sequence is shown in Figure 2. The fragments of enoxaparin
that do not possess anticoagulant activity are reported to
be responsible for heparin’s non-anticoagulant activity,
including anti-inflammatory effect. Given the potential of
enoxaparin in LP, future studies should aim for identification
and structural elucidation of therapeutically active non-
anticoagulant fragments. After identifying the fragments of
enoxaparin and establishing dose-response relationships,
their structural elucidation should be carried out using
sophisticated techniques such as mass spectrometry and
nuclear magnetic resonance. Once the structures of active
fragments are established, structure-activity relationships
should provide important information on the precise location
and sulfation pattern required for the anti-inflammatory
activity.
As a new formulation containing identified fragments would
have been derived from commercially available enoxaparin, it
may face patent and regulatory approval related complications.
Elucidation of structure-activity relationships would enable
the structural modification of identified fragments without
compromising their clinical efficacy in LP. Such an approach
would allow the synthesis of new compounds, structurally
different from the active non-anticoagulant fragments of
enoxaparin, without losing the anti-inflammatory effect. Using
a similar approach, an ultra LMWH (known as fondaparinux)
was developed and is currently used for the treatment of deep
vein thrombosis and acute pulmonary embolism. Fondaparinux
is a synthetic pentasaccharide devoid of other non-anticoagulant
fragments present in various types of heparins. Therefore, it
does not bind to various plasma proteins other than anti-
thrombin.
Mechanism of Action of Active
Non-anticoagulant Fractions of
Enoxaparin
The mechanisms by which enoxaparin exerts its therapeutic
effect in LP is currently unknown. Therefore, future research
should investigate the possible mode of action of identified
non-anticoagulant fragments of enoxaparin in LP. So far,
only one study has investigated the possible mechanisms by
which non-anticoagulant fragments of enoxaparin inhibited
the release of inflammatory cytokines (Shastri et al., 2015a,c).
In this study, the peripheral blood mononuclear cells were
collected from asthmatic patients and then the cells were
stimulated using lectins, such as phytohaemagglutinin and
concanavalin A, in the presence or absence of various non-
anticoagulant fragments of enoxaparin. The authors concluded
that the potential mechanism by which the tested fragments
suppressed the inflammatory response was through directly
interacting with cell surface receptors and covering different
signaling pathways. However, it remains to be seen if such
inhibition is limited to stimulation of cells through plant
FIGURE 2 | Pentasaccharide sequence of heparin. The binding between this specific sequence and antithrombin III results in the anticoagulant effect of heparin.
Reproduced with permission (Patel et al., 2009c).
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lectins or is extended to antigen-specific activation of the T cell
receptor.
CONCLUSION
One of the important reasons for the observed inconsistent
clinical outcomes when enoxaparin has been studied for
the treatment of LP could be the presence of structurally
different non-anticoagulant fragments in different batches of
enoxaparin. Based on the available scientific evidence, the
authors believe that enoxaparin may play an important role
in the management of LP and its potential must be explored
using well-designed clinical trials and experimental studies
that focus on identifying the anti-inflammatory fragments
of enoxaparin and elucidating the mechanism of actions
and appropriate therapeutic doses of these non-anticoagulant
fragments.
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